These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 6753611)

  • 1. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine.
    Davis KL; Mohs RC
    Am J Psychiatry; 1982 Nov; 139(11):1421-4. PubMed ID: 6753611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial.
    Jenike MA; Albert MS; Heller H; Gunther J; Goff D
    J Clin Psychiatry; 1990 Jan; 51(1):3-7. PubMed ID: 2403997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral physostigmine and lecithin improve memory in Alzheimer disease.
    Thal LJ; Fuld PA; Masur DM; Sharpless NS
    Ann Neurol; 1983 May; 13(5):491-6. PubMed ID: 6347034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of oral physostigmine in primary degenerative dementia. A double-blind study of response to different dose level.
    Beller SA; Overall JE; Swann AC
    Psychopharmacology (Berl); 1985; 87(2):147-51. PubMed ID: 3931138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Memory enhancement with oral physostigmine in Alzheimer's disease.
    N Engl J Med; 1983 Mar; 308(12):720-1. PubMed ID: 6338388
    [No Abstract]   [Full Text] [Related]  

  • 6. Physostigmine effects in Alzheimer's disease: relationship to dementia severity.
    Schwartz AS; Kohlstaedt EV
    Life Sci; 1986 Mar; 38(11):1021-8. PubMed ID: 3512944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical studies of the cholinergic deficit in Alzheimer's disease. II. Psychopharmacologic studies.
    Mohs RC; Davis BM; Greenwald BS; Mathé AA; Johns CA; Horvath TB; Davis KL
    J Am Geriatr Soc; 1985 Nov; 33(11):749-57. PubMed ID: 2865282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physostigmine and its effect on six patients with dementia.
    Ashford JW; Soldinger S; Schaeffer J; Cochran L; Jarvik LF
    Am J Psychiatry; 1981 Jun; 138(6):829-30. PubMed ID: 7246817
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of oral physostigmine in Alzheimer's disease.
    Stern Y; Sano M; Mayeux R
    Ann Neurol; 1987 Sep; 22(3):306-10. PubMed ID: 3674795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of physostigmine and lecithin on memory in Alzheimer disease.
    Peters BH; Levin HS
    Ann Neurol; 1979 Sep; 6(3):219-21. PubMed ID: 534419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Alzheimer disease by continuous intravenous infusion of physostigmine.
    Asthana S; Raffaele KC; Berardi A; Greig NH; Haxby JV; Schapiro MB; Soncrant TT
    Alzheimer Dis Assoc Disord; 1995; 9(4):223-32. PubMed ID: 8749612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia.
    Christie JE; Shering A; Ferguson J; Glen AI
    Br J Psychiatry; 1981 Jan; 138():46-50. PubMed ID: 7023592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral physostigmine treatment of patients with Alzheimer's disease.
    Mohs RC; Davis BM; Johns CA; Mathé AA; Greenwald BS; Horvath TB; Davis KL
    Am J Psychiatry; 1985 Jan; 142(1):28-33. PubMed ID: 3881051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of fusiform cortex activity by cholinesterase inhibition predicts effects on subsequent memory.
    Bentley P; Driver J; Dolan RJ
    Brain; 2009 Sep; 132(Pt 9):2356-71. PubMed ID: 19605530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved verbal learning after outpatient oral physostigmine therapy in patients with dementia of the Alzheimer type.
    Sevush S; Guterman A; Villalon AV
    J Clin Psychiatry; 1991 Jul; 52(7):300-3. PubMed ID: 2071560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physostigmine in Alzheimer's disease.
    Smith CM; Swash M
    Lancet; 1979 Jan; 1(8106):42. PubMed ID: 83485
    [No Abstract]   [Full Text] [Related]  

  • 17. Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease.
    Thal LJ; Masur DM; Blau AD; Fuld PA; Klauber MR
    J Am Geriatr Soc; 1989 Jan; 37(1):42-8. PubMed ID: 2642499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A signal detectability analysis of the effect of physostigmine on memory in patients with Alzheimer's disease.
    Mohs RC; Davis KL
    Neurobiol Aging; 1982; 3(2):105-10. PubMed ID: 6752738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease.
    Wettstein A
    Ann Neurol; 1983 Feb; 13(2):210-2. PubMed ID: 6830183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term administration of oral physostigmine in Alzheimer's disease.
    Stern Y; Sano M; Mayeux R
    Neurology; 1988 Dec; 38(12):1837-41. PubMed ID: 3057398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.